EBV-TCR-T cells for persistent EBV after stem cell transplant
Part of Infections clinical trials.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a stem cell transplant from a donor.
- You have tested positive for Epstein-Barr virus (EBV) in your blood, and it has not gone away with usual treatments.
- You are feeling well enough to do daily activities (ECOG score 0-2).
- You do not have certain other uncontrolled infections or serious autoimmune conditions.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving special immune cells (called cytotoxic T lymphocytes) can fight viruses like CMV, adenovirus, EBV, or BK virus that are not responding to usual treatments. It is for people aged 0 to 29 with weakened immune systems due to inherited conditions or previous transplants.
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
This trial tests a new immune cell therapy (EBV-TCR-T cells) for people with a severe immune reaction caused by the Epstein-Barr virus (EBV-HLH) or active EBV infection. The treatment uses special cells from a matched donor to help your body fight the virus.
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
This trial tests whether giving rituximab early after a stem cell transplant can prevent a common viral infection (EBV) from becoming serious. It may help reduce complications and improve recovery.
Hear when a new Post-Transplant Lymphoproliferative Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.